C12N 2501/585
Integrins
C12N2501/585 (Integrins) appears on 32 US grants and 54 published applications in this corpus.
Search patents in C12N- Granted patents
- 32
- Published applications
- 54
- Assignees
- 35
- Inventors
- 106
- Latest grant
- 11 Mar 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 3 |
| 2003 | 1 | 1 |
| 2004 | 2 | 5 |
| 2005 | 1 | 0 |
| 2006 | 0 | 2 |
| 2007 | 1 | 0 |
| 2008 | 2 | 4 |
| 2009 | 0 | 1 |
| 2010 | 3 | 5 |
| 2011 | 1 | 2 |
| 2012 | 0 | 1 |
| 2013 | 1 | 0 |
| 2014 | 1 | 1 |
| 2015 | 2 | 2 |
| 2016 | 2 | 0 |
| 2017 | 1 | 4 |
| 2018 | 2 | 2 |
| 2019 | 1 | 3 |
| 2020 | 1 | 5 |
| 2021 | 0 | 1 |
| 2022 | 2 | 4 |
| 2023 | 3 | 2 |
| 2024 | 1 | 1 |
| 2025 | 1 | 3 |
| 2026 | 0 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Quality assurance of chondrocytes11 Mar 2025US 12,247,222 B2Xintela AB
- Periostin compounds for the treatment of haematological complications10 Dec 2024US 12,162,918 B2Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus
- T-cell modulatory multimeric polypeptides and methods of use thereof26 Dec 2023US 11,851,471 B2Cue Biopharma, Inc.
- Quality assurance of chondrocytes15 Aug 2023US 11,725,188 B2Xintela AB
- Isolation of bona fide pancreatic progenitor cells28 Mar 2023US 11,613,736 B2University of Copenhagen
- Methods for making auditory progenitor cells and uses thereof7 May 2026US 2026/0124247 A1The Regents of the University of California
- Kit for diagnosing alzheimer's disease and pharmaceutical composition for treating alzheimer's disease12 Feb 2026US 2026/0043791 A1Eisai R&D Management Co., Ltd.
- Periostin compounds for the treatment of haematological complications30 Oct 2025US 2025/0333462 A1Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus
- Differentiation induction control agent and differentiation induction stabilizing agent for pluripotent stem cells22 May 2025US 2025/0163369 A1Osaka University
- Marker for Neural Stem Cells16 Jan 2025US 2025/0020646 A1Xintela AB
Most cited
By later US patents
- Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds113US 6,958,212 B1Eidgenossische Technische Hochschule Zurich · 2005
- Cell rolling separation73US 8,986,988 B2Massachusetts Institute of Technology · 2015
- Process for ex vivo formation of mammalian bone and uses thereof45US 6,811,776 B2The Regents of the University of Michigan · 2004
- Method for restoration of normal phenotype in cancer cells21US 6,123,941 AThe Regents of the University of California · 2000
- Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds16US 7,413,739 B2Eidgenossische Technische Hochschule Zurich · 2008